Comparative Pharmacology
Head-to-head clinical analysis: BUPROPION HYDROBROMIDE versus DESYREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPROPION HYDROBROMIDE versus DESYREL.
BUPROPION HYDROBROMIDE vs DESYREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupropion is an aminoketone antidepressant that acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It also noncompetitively inhibits nicotinic acetylcholine receptors, contributing to smoking cessation efficacy. The exact mechanism for antidepressant effect is unknown but is thought to be related to noradrenergic and dopaminergic modulation.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking serotonin reuptake at the presynaptic neuron. Also has secondary antagonistic effects at 5-HT2A receptors, contributing to its antidepressant and anxiolytic effects.
150 mg orally once daily; after 3 days, may increase to 300 mg orally once daily (administer as 150 mg twice daily) for major depressive disorder. For smoking cessation: 150 mg orally once daily for 3 days, then 150 mg orally twice daily.
Initial dose: 150 mg orally once daily, increased by 50 mg/day every 3-4 days. Maximum: 400 mg/day. For severe depression, up to 600 mg/day in hospitalized patients.
None Documented
None Documented
Terminal half-life ~20 hours (range 12-30). Clinical note: Steady state in 4-5 days; active metabolites (hydroxybupropion, threohydrobupropion, erythrohydrobupropion) have longer half-lives (20-37 hours) contributing to prolonged effects.
Terminal elimination half-life is approximately 5-11 hours (mean 7 hours); for elderly patients, half-life may be prolonged.
Primarily renal (87%), with 10% fecal. Unchanged bupropion in urine <1%.
Primarily renal (approximately 75% as metabolites, less than 1% unchanged); fecal excretion accounts for about 20%.
Category A/B
Category C
Atypical Antidepressant
Atypical Antidepressant